Epidemiology, pathology and treatment of non-follicular indolent lymphomas

Leukemia and Lymphoma

Volumn 49, Issue SUPPL. 1, 2008, Pages 35-42

  Landgren, Ola ^a   Tilly, Hervé ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b CENTRE HENRI BECQUEREL   (France)

Author keywords

Indolent lymphoma; Non follicular lymphoma; Non Hodgkin lymphoma

Indexed keywords

ANTIBIOTIC AGENT; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; INTERFERON; NUCLEOSIDE ANALOG; PREDNISONE; RIBAVIRIN; RITUXIMAB; VINCRISTINE;

ARTICLE; AUTOIMMUNITY; BACTERIAL INFECTION; CANCER INCIDENCE; CANCER RISK; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; GENETIC RISK; HELICOBACTER INFECTION; HEPATITIS C; HUMAN; LYMPHOMA; MARGINAL ZONE LYMPHOMA; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; NODAL MARGINAL ZONE LYMPHOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SMALL LYMPHOCYTIC LYMPHOMA; SPLENECTOMY; SPLENIC MARGINAL ZONE LYMPHOMA;

HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, B-CELL; LYMPHOMA, B-CELL, MARGINAL ZONE; RISK FACTORS;

EID: 53249134734     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190802311425     Document Type: Article

References (64)

1. Adult non-Hodgkin's lymphoma treatment
2. Seng, J. E. and Peterson, B. A. (1997) Indolent B-cell non-Hodgkin's lymphomas. Oncology, 11, pp. 1883-1894.
3. Turesson, I., Linet, M. S., Bjorkholm, M., Kristinsson, S. Y., Goldin, L. R. Caporaso, N. E. et al. (2007) Ascertainment and diagnostic accuracy for hematopoietic lymphoproliferative malignancies in Sweden 1964-2003. Int J Cancer, 121, pp. 2260-2266.
4. Landgren, O., Bjorkholm, M., Montgomery, S. M., Hjalgrim, H., Sjoberg, J. Goldin, L. R. et al. (2006) Personal and family history of autoimmune diabetes mellitus and susceptibility to young-adult-onset Hodgkin lymphoma. Int J Cancer, 118, pp. 449-452.
5. Landgren, O., Engels, E. A., Caporaso, N. E., Gridley, G., Mellemkjaer, L. Hemminki, K. et al. (2006) Patterns of autoimmunity and subsequent chronic lymphocytic leukemia in Nordic countries. Blood, 108, pp. 292-296.
6. Landgren, O., Linet, M. S., McMaster, M. L., Gridley, G., Hemminki, K. and Goldin, L. R. (2006) Familial characteristics of autoimmune and hematologic disorders in 8,406 multiple myeloma patients: A population-based case-control study. Int J Cancer, 118, pp. 3095-3098.
7. Landgren, O., Rapkin, J. S., Caporaso, N. E., Mellemkjaer, L., Gridley, G. Goldin, L. R. et al. (2007) Respiratory tract infections and subsequent risk of chronic lymphocytic leukemia. Blood, 109, pp. 2198-2201.
8. Mellemkjaer, L., Andersen, V., Linet, M. S., Gridley, G., Hoover, R. and Olsen, J. H. (1997) Non-Hodgkin's lymphoma and other cancers among a cohort of patients with systemic lupus erythematosus. Arthritis Rheum, 40, pp. 761-768.
9. Chiorazzi, N., Rai, K. R. and Ferrarini, M. (2005) Chronic lymphocytic leukemia. N Engl J Med, 352, pp. 805-815.
10. Stamatopoulos, K., Belessi, C., Moreno, C., Boudjograh, M., Guida, G. Smilevska, T. et al. (2007) Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: Pathogenetic implications and clinical correlations. Blood, 109, pp. 259-270.
11. Miklos, J. A., Swerdlow, S. H. and Bahler, D. W. (2000) Salivary gland mucosa-associated lymphoid tissue lymphoma immunoglobulin V(H) genes show frequent use of V1-69 with distinctive CDR3 features. Blood, 95, pp. 3878-3884.
12. Marasca, R., Vaccari, P., Luppi, M., Zucchini, P., Castelli, I. Barozzi, P. et al. (2001) Immunoglobulin gene mutations and frequent use of VH1-69 and VH4-34 segments in hepatitis C virus-positive and hepatitis C virus-negative nodal marginal zone B-cell lymphoma. Am J Pathol, 159, pp. 253-261.
13. Algara, P., Mateo, M. S., Sanchez-Beato, M., Mollejo, M., Navas, I. C. Romero, L. et al. (2002) Analysis of the IgV(H) somatic mutations in splenic marginal zone lymphoma defines a group of unmutated cases with frequent 7q deletion and adverse clinical course. Blood, 99, pp. 1299-1304.
14. Camacho, F. I., Algara, P., Rodriguez, A., Ruiz-Ballesteros, E., Mollejo, M. Martinez, N. et al. (2003) Molecular heterogeneity in MCL defined by the use of specific VH genes and the frequency of somatic mutations. Blood, 101, pp. 4042-4046.
15. Stamatopoulos, K., Belessi, C., Papadaki, T., Kalagiakou, E., Stavroyianni, N. Douka, V. et al. (2004) Immunoglobulin heavy- and light-chain repertoire in splenic marginal zone lymphoma. Mol Med, 10, pp. 89-95.
16. Goldin, L. R., Landgren, O., McMaster, M. L., Gridley, G., Hemminki, K. Li, X. et al. (2005) Familial aggregation and heterogeneity of non-Hodgkin lymphoma in population-based samples. Cancer Epidemiol Biomarkers Prev, 14, pp. 2402-2406.
17. Goldin, L. R., Pfeiffer, R. M., Li, X. and Hemminki, K. (2004) Familial risk of lymphoproliferative tumors in families of patients with chronic lymphocytic leukemia: Results from the Swedish Family-Cancer Database. Blood, 104, pp. 1850-1854.
18. Goldin, L. R., Pfeiffer, R. M., Gridley, G., Gail, M. H., Li, X. Mellemkjaer, L. et al. (2004) Familial aggregation of Hodgkin lymphoma and related tumors. Cancer, 100, pp. 1902-1908.
19. Marti, G. E., Rawstron, A. C., Ghia, P., Hillmen, P., Houlston, R. S. Kay, N. et al. (2005) Diagnostic criteria for monoclonal B-cell lymphocytosis. Br J Haematol, 130, pp. 325-332.
20. Landgren, O. and Kyle, R. A. (2007) Multiple myeloma, chronic lymphocytic leukaemia and associated precursor diseases. Br J Haematol, 139, pp. 717-723.
21. Thomas, R., Ribeiro, I., Shepherd, P., Johnson, P., Cook, M. Lakhani, A. et al. (2002) Spontaneous clinical regression in chronic lymphocytic leukaemia. Br J Haematol, 116, pp. 341-345.
22. Harris, N. L., Jaffe, E. S., Diebold, J., Flandrin, G., Muller-Hermelink, H. K. Vardiman, J. et al. (1999) World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol, 17, pp. 3835-3849.
23. Rai, K. R., Sawitsky, A., Cronkite, E. P., Chanana, A. D., Levy, R. N. and Pasternack, B. S. (1975) Clinical staging of chronic lymphocytic leukemia. Blood, 46, pp. 219-234.
24. Binet, J. L., Auquier, A., Dighiero, G., Chastang, C., Piguet, H. Goasguen, J. et al. (1981) A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer, 48, pp. 198-206.
25. Hallek, M., Cheson, B. D., Catovsky, D., Caligaris-Cappio, F., Dighiero, G. Dohner, H. et al. (2008) Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) updating the National Cancer Institute-Working Group (NCI-WG) 1996 guidelines. Blood, 12, pp. 5446-5556.
26. Tsimberidou, A. M., Wen, S., O'Brien, S., McLaughlin, P., Wierda, W. G. Ferrajoli, A. et al. (2007) Assessment of chronic lymphocytic leukemia and small lymphocytic lymphoma by absolute lymphocyte counts in 2,126 patients: 20 years of experience at the University of Texas M.D. Anderson Cancer Center. J Clin Oncol, 25, pp. 4648-4656.
27. Arcaini, L., Paulli, M., Boveri, E., Magrini, U. and Lazzarino, M. (2003) Marginal zone-related neoplasms of splenic and nodal origin. Haematologica, 88, pp. 80-93.
28. Ferreri, A. J. and Zucca, E. (2007) Marginal-zone lymphoma. Crit Rev Oncol Hematol, 63, pp. 245-256.
29. Thieblemont, C. and Coiffier, B. (2006) Management of marginal zone lymphomas. Curr Treat Options Oncol, 7, pp. 213-222.
30. Cualing, H., Steele, P. and Zellner, D. (2000) Blastic transformation of splenic marginal zone B-cell lymphoma. Arch Pathol Lab Med, 124, pp. 748-752.
31. Oscier, D., Owen, R. and Johnson, S. (2005) Splenic marginal zone lymphoma. Blood Rev, 19, pp. 39-51.
32. Audouin, J., Le Tourneau, A, Molina, T., Camilleri-Broët, S., Adida, C. Comperat, E. et al. (2003) Patterns of bone marrow involvement in 58 patients presenting primary splenic marginal zone lymphoma with or without circulating villous lymphocytes. Br J Haematol, 122, pp. 404-412.
33. Camacho, F. I., Mollejo, M., Mateo, M. S., Algara, P., Navas, C. Hernandez, J. M. et al. (2001) Progression to large B-cell lymphoma in splenic marginal zone lymphoma: A description of a series of 12 cases. Am J Surg Pathol, 25, pp. 1268-1276.
34. Parsonnet, J. and Isaacson, P. G. (2004) Bacterial infection and MALT lymphoma. N Engl J Med, 350, pp. 213-215.
35. Dallenbach, F. E., Coupland, S. E. and Stein, H. (2000) Marginal zone lymphomas: Extranodal MALT type, nodal and splenic. Pathologe, 21, pp. 162-177.
36. Levy, M., Copie-Bergman, C., Traulle, C., Lavergne-Slove, A., Brousse, N. Flejou, J. F. et al. (2002) Conservative treatment of primary gastric low-grade B-cell lymphoma of mucosa-associated lymphoid tissue: predictive factors of response and outcome. Am J Gastroenterol, 97, pp. 292-297.
37. Liu, H., Ye, H., Ruskone-Fourmestraux, A., De Jong, D., Pileri, S. Thiede, C. et al. (2002) t(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradication. Gastroenterology, 122, pp. 1286-1294.
38. Wundisch, T., Thiede, C., Morgner, A., Dempfle, A., Gunther, A. Liu, H. et al. (2005) Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication. J Clin Oncol, 23, pp. 8018-8024.
39. Yeh, K. H., Kuo, S. H., Chen, L. T., Mao, T. L., Doong, S. L. Wu, M. S. et al. (2005) Nuclear expression of BCL10 or nuclear factor kappa B helps predict Helicobacter pylori-independent status of low-grade gastric mucosa-associated lymphoid tissue lymphomas with or without t(11;18)(q21;q21). Blood, 106, pp. 1037-1041.
40. Martinelli, G., Laszlo, D., Ferreri, A. J., Pruneri, G., Ponzoni, M. Conconi, A. et al. (2005) Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy. J Clin Oncol, 23, pp. 1979-1983.
41. Saadoun, D., Suarez, F., Lefrere, F., Valensi, F., Mariette, X. Aouba, A. et al. (2005) Splenic lymphoma with villous lymphocytes, associated with type II cryoglobulinemia and HCV infection: A new entity?. Blood, 105, pp. 74-76.
42. Franco, V., Florena, A. M. and Iannitto, E. (2003) Splenic marginal zone lymphoma. Blood, 101, pp. 2464-2472.
43. Matutes, E., Oscier, D., Montalban, C., Berger, F., Callet-Bauchu, E. Dogan, A. et al. (2008) Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria. Leukemia, 22, pp. 487-495.
44. Kent, S. A., Variakojis, D. and Peterson, L. C. (2002) Comparative study of marginal zone lymphoma involving bone marrow. Am J Clin Pathol, 117, pp. 698-708.
45. Thieblemont, C., Felman, P., Berger, F., Dumontet, C., Arnaud, P. Hequet, O. et al. (2002) Treatment of splenic marginal zone B-cell lymphoma: An analysis of 81 patients. Clin Lymphoma, 3, pp. 41-47.
46. Arcaini, L., Lazzarino, M., Colombo, N., Burcheri, S., Boveri, E. Paulli, M. et al. (2006) Splenic marginal zone lymphoma: A prognostic model for clinical use. Blood, 107, pp. 4643-4649.
47. Thieblemont, C., Felman, P., Callet-Bauchu, E. Traverse-Glehen, A. et al. (2003) Splenic marginal-zone lymphoma: A distinct clinical and pathological entity. Lancet Oncol, 4, pp. 95-103.
48. Chacon, J. I., Mollejo, M., Munoz, E., Algara, P., Mateo, M. Lopez, L. et al. (2002) Splenic marginal zone lymphoma: Clinical characteristics and prognostic factors in a series of 60 patients. Blood, 100, pp. 1648-1654.
49. Kalpadakis, C., Pangalis, G. A., Dimopoulou, M. N., Vassilakopoulos, T. P., Kyrtsonis, M. C. Korkolopoulou, P. et al. (2007) Rituximab monotherapy is highly effective in splenic marginal zone lymphoma. Hematol Oncol, 25, pp. 127-131.
50. Tsimberidou, A. M., Catovsky, D., Schlette, E., O'Brien, S., Wierda, W. G. Kantarjian, H. et al. (2006) Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone. Cancer, 107, pp. 125-135.
51. Arcaini, L., Paulli, M., Boveri, E., Vallisa, D., Bernuzzi, P. Orlandi, E. et al. (2004) Splenic and nodal marginal zone lymphomas are indolent disorders at high hepatitis C virus seroprevalence with distinct presenting features but similar morphologic and phenotypic profiles. Cancer, 100, pp. 107-115.
52. Mele, A., Pulsoni, A., Bianco, E., Musto, P., Szklo, A. Sanpaolo, M. G. et al. (2003) Hepatitis C virus and B-cell non-Hodgkin lymphomas: An Italian multicenter case-control study. Blood, 102, pp. 996-999.
53. Zuckerman, E., Zuckerman, T., Levine, A. M., Douer, D., Gutekunst, K. Mizokami, M. et al. (1997) Hepatitis C virus infection in patients with B-cell non-Hodgkin lymphoma. Ann Intern Med, 127, pp. 423-428.
54. Suarez, F., Lefrere, F., Besson, C. and Hermine, O. (2007) Splenic lymphoma with villous lymphocytes, mixed cryoglobulinemia and HCV infection: Deciphering the role of HCV in B-cell lymphogenesis. Dig Liver Dis, 39, pp. S32-S37.
55. Silvestri, F., Pipan, C., Barillari, G., Zaja, F., Fanin, R. Infanti, L. et al. (1996) Prevalence of hepatitis C virus infections in patients with lymphoproliferative disorders. Blood, 87, pp. 4296-4301.
56. Vallisa, D., Bernuzzi, P., Arcaini, L., Sacchi, S., Callea, V. Marasca, R. et al. (2005) Role of anti-hepatitis C virus (HCV) treatment in HCV-related, low-grade, B-cell, non-Hodgkin's lymphoma: A multicenter Italian experience. J Clin Oncol, 23, pp. 468-473.
57. Hermine, O., Lefrere, F., Bronowicki, J. P., Mariette, X., Jondeau, K. Eclache-Saudreau, V. et al. (2002) Regression of splenic lymphoma with villous lymphocytes after treatment of Hepatitis C virus infection. N Engl J Med, 347, pp. 89-94.
58. Berger, F., Felman, P., Thieblemont, C., Pradier, T., Baseggio, L. Bryon, P. A. et al. (2000) Non-MALT marginal zone B-cell lymphomas: A description of clinical presentation and outcome in 124 patients. Blood, 95, pp. 1950-1956.
59. Arcaini, L., Paulli, M., Burcheri, S., Rossi, A., Spina, M. Passamonti, F. et al. (2007) Primary nodal marginal zone B-cell lymphoma: Clinical features and prognostic assessment of a rare disease. Br J Haematol, 136, pp. 301-304.
60. Nathwani, B. N., Anderson, J. R., Armitage, J. O., Cavalli, F., Diebold, J. Drachenberg, M. R. et al. (1999) Marginal zone B-cell lymphoma: A clinical comparison of nodal and mucosa-associated lymphoid tissue types. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol, 17, pp. 2486-2492.
61. Traverse-Glehen, A., Felman, P., Callet-Bauchu, E., Gazzo, S., Baseggio, L. Bryon, P. A. et al. (2006) A clinicopathological study of nodal marginal zone B-cell lymphoma. A report on 21 cases. Histopathology, 88, pp. 162-173.
62. Oh, S. Y., Ryoo, B. Y., Kim, W. S., Kim, K., Lee, J. Kim, H. J. et al. (2006) Nodal marginal zone B-cell lymphoma: Analysis of 36 cases. Clinical presentation and treatment outcomes of nodal marginal zone B-cell lymphoma. Ann Hematol, 86, pp. 781-786.
63. Koh, L. P., Lim, L. C. and Thng, C. H. (2000) Retreatment with chimeric CD 20 monoclonal antibody in a patient with nodal marginal zone B-cell lymphoma. Med Oncol, 17, pp. 225-228.
64. Mollejo, M., Camacho, F. I., Algara, P., Ruiz-Ballesteros, E., Garcia, J. F. and Piris, M. A. (2005) Nodal and splenic marginal zone B cell lymphomas. Hematol Oncol, 23, pp. 108-118.